Calendar

TIAN RUIXIANG Holdings Ltd Receives Notification of Non-compliance from Nasdaq Relating to Late Filing of Annual Report on Form 20-F

Retrieved on: 
Monday, March 25, 2024
Annual report, Security (finance), Lung compliance, Calendar

BEIJING, March 25, 2024 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the "Company"), a China-based insurance broker conducting business through its variable interest entity in China, today announced that on March 20, 2024, it received a notice of non-compliance from Nasdaq Listing Qualifications which states that, as a result of not having timely filed its annual report on Form 20-F for the fiscal year ended October 31, 2023 (the "2023 Form 20-F"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission (the "SEC").

Key Points: 
  • BEIJING, March 25, 2024 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the "Company"), a China-based insurance broker conducting business through its variable interest entity in China, today announced that on March 20, 2024, it received a notice of non-compliance from Nasdaq Listing Qualifications which states that, as a result of not having timely filed its annual report on Form 20-F for the fiscal year ended October 31, 2023 (the "2023 Form 20-F"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission (the "SEC").
  • This notice has no immediate effect on the listing or trading of TIRX's Class A ordinary shares on the Nasdaq Capital Market.
  • Under Nasdaq’s listing rules, the Company has 60 calendar days, or until May 20, 2024, to submit a plan to regain compliance.
  • If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the 2023 Form 20-F's due date, or until September 10, 2024, to regain compliance.

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Retrieved on: 
Monday, March 25, 2024
AbbVie, Ulcerative colitis, Patient, Inflammation, ABBV, Acquisition, IBD, MOA, Therapy, NLRX1, Calendar, Pharmaceutical industry

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

Key Points: 
  • NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
  • Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
  • “NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn’s disease.
  • The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos’ stockholders.

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Retrieved on: 
Monday, March 25, 2024
Toxicity, Therapeutic index, Conference, Human, Docetaxel, Webcast, Weight loss, LNC, Neoplasm, Mouse, Calendar, Melanoma, Lecture, Pharmaceutical industry

BEDMINSTER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces positive results from an additional in vivo study in healthy mice with an oral LNC formulation of docetaxel, a well-established chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors. Docetaxel is currently only administered intravenously and is frequently associated with significant side effects and treatment-limiting toxicities.

Key Points: 
  • "These recent data show how our oral LNC-docetaxel formulation can dramatically reduce the well-recognized toxicity of IV-docetaxel, as primarily manifested by weight loss in this model,” said James J. Ferguson, M.D., Chief Medical Officer of Matinas .
  • We have now corroborated this lack of toxicity in a more comprehensive safety study with a longer treatment duration and even higher doses of oral LNC-docetaxel.
  • Mice treated with oral LNC-docetaxel maintained their body weight, which was statistically no different than the weight of control mice treated with oral saline.
  • The webcast will be available on the IR Calendar page of the Matinas website and will be archived for six months.

POET Technologies Announces Intention to Amend Warrant Terms

Retrieved on: 
Friday, March 22, 2024
Indian stock exchange, TSX Venture Exchange, Exchange, Acceleration, The, Warrant, News, Die (integrated circuit), POET, Programmable interrupt controller, Amendment, Calendar, PTK, Security (finance)

Each Warrant is currently exercisable by the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at an exercise price of C$4.95 (US$3.61) per Common Share until December 2, 2025.

Key Points: 
  • Each Warrant is currently exercisable by the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at an exercise price of C$4.95 (US$3.61) per Common Share until December 2, 2025.
  • In accordance with the terms of the Warrants and the policies of the Exchange, the Corporation must obtain the consent of all holders of Warrants in order to give effect to the Amendments.
  • Upon the Amendments becoming effective, each Warrant will be exercisable until 5:00 p.m. (Toronto time) on December 2, 2025, at an exercise price of C$1.80 (US$1.33) per Common Share.
  • The amended warrant terms remain subject to the final acceptance of the Exchange.

TSS, INC. TO REPORT FOURTH QUARTER AND FISCAL 2023 RESULTS ON THURSDAY, MARCH 28th, 2024

Retrieved on: 
Thursday, March 21, 2024
TSSI, TSS, ID, Webcast, Calendar, Software

ROUND ROCK, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- TSS, Inc. (Other OTC: TSSI), a data center services company that integrates high-performance computing infrastructure and software, will report financial results for its fourth quarter and fiscal 2023 on Thursday March 28th, 2024.

Key Points: 
  • ROUND ROCK, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- TSS, Inc. (Other OTC: TSSI), a data center services company that integrates high-performance computing infrastructure and software, will report financial results for its fourth quarter and fiscal 2023 on Thursday March 28th, 2024.
  • The Company will conduct a conference call at 4.30 p.m. eastern time that day.
  • To participate on the conference call, please dial 1-888-596-4144 toll free from the U.S., or 1-646-968-2525 for international callers.
  • An audio replay of the conference call will be available approximately four hours after the conclusion of the call and will be made available until April 28, 2024.

Broad Arrow Announces Continued Expansion into the UK and EU with the Addition of Five New Team Members, including Veteran Car Specialists Joe Twyman and Robert Glover

Retrieved on: 
Thursday, March 21, 2024
Lancia, Growth, Lamborghini, Yves, Broad arrow, Romeos, Post-war, Porsche, Alfa, Touring car, Sale, Pointe technique, University, Land Rover, Essen Motor Show, BMW, Jaguar, Bonhams, Le Mans, Gooding & Company, Calendar, Collection, Lukas, Economics, Car, Nightclub

Joe joins Broad Arrow as Director and Head of UK and European Consignments following an eight-year tenure working with Gooding & Company.

Key Points: 
  • Joe joins Broad Arrow as Director and Head of UK and European Consignments following an eight-year tenure working with Gooding & Company.
  • Based in the UK with strong ties to Europe, Joe frequently travels to meet clients, attend events, and inspect cars.
  • Robert joins Broad Arrow Group as a consignment specialist with 20-plus years of experience within the collector car industry.
  • Prior to joining Broad Arrow, Matt developed a career background in the automotive industry, working for BMW and Land Rover.

Tritium Receives Nasdaq Delisting Determination

Retrieved on: 
Thursday, March 21, 2024
Deficiency, Delisting, Calendar, Hearing, Cryptocurrency

BRISBANE, Australia, March 21, 2024 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Nasdaq: DCFC) (“Tritium” or the “Company”), a global developer and manufacturer of direct current (“DC”) fast chargers for electric vehicles (“EVs”), today announced that on March 15, 2024 the Company received a delisting determination notice (the “Delisting Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”).

Key Points: 
  • BRISBANE, Australia, March 21, 2024 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Nasdaq: DCFC) (“Tritium” or the “Company”), a global developer and manufacturer of direct current (“DC”) fast chargers for electric vehicles (“EVs”), today announced that on March 15, 2024 the Company received a delisting determination notice (the “Delisting Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”).
  • In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided a period of 180 calendar days, or until April 9, 2024, to regain compliance with the Minimum Bid Price Requirement.
  • On March 15, 2024, the Company received the subsequent Delisting Notice from Nasdaq notifying the Company that, as of March 15, 2024, the Company's ordinary shares had a closing bid price of $0.10 or less for ten consecutive trading days and that, consistent with Nasdaq Listing Rule 5810(c)(3)(A)(iii), Nasdaq had determined to begin the process to delist the Company's common stock from the Nasdaq Global Market.
  • On March 22, 2024, the Company intends to submit a request for a hearing before the Nasdaq Hearings Panel to appeal the Delisting Notice.

Enact Releases 2023 Environmental, Social, and Governance (ESG) Report

Retrieved on: 
Wednesday, March 20, 2024
ACT, Failure, Communication, ESG, Security (finance), Risk, Federal Housing Administration, U.N, TCFD, Annual report, Calendar, Freddie Mac, Fannie Mae, Task force

RALEIGH, N.C., March 20, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) today announced the release of its 2023 Environmental, Social, and Governance (ESG) Report covering the calendar year 2023.

Key Points: 
  • RALEIGH, N.C., March 20, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) today announced the release of its 2023 Environmental, Social, and Governance (ESG) Report covering the calendar year 2023.
  • This report builds upon Enact’s inaugural ESG report published in 2023, for the calendar year 2022, by providing additional insight into Enact’s approach to ESG matters and highlighting progress across our ESG priorities, along with new insights that provide additional transparency into Enact’s ESG journey.
  • The new insights include additional disclosures relating to the Taskforce on Climate-related Financial Disclosures (TCFD) and the United Nations Sustainable Development Goals (U.N. SDGs) frameworks.
  • “On behalf of everyone at Enact, I am pleased to share the next installment in our efforts to build a more inclusive and sustainable future for our customers, employees, investors and communities,” said Rohit Gupta, President and CEO of Enact.

authID Inc. Reports Financial and Operating Results for the Fiscal Year Ended December 31, 2023

Retrieved on: 
Wednesday, March 20, 2024
Momentum, Conference, Growth, RPO, ISMS, Webcast, Patient, Information, EDT, News, Fintech, Certification, ABM Industries, Zoom, Fortune 500, Confidentiality, Workforce, ID, Digital technology, Calendar, ABM, Fiscal, Engineering

DENVER, March 20, 2024 (GLOBE NEWSWIRE) -- authID Inc. (Nasdaq: AUID), a leading provider of innovative biometric identity verification and authentication solutions, today reported financial and operating results for the full year ended December 31, 2023.

Key Points: 
  • The reduction was primarily attributed to revenue from a legacy authentication product that was discontinued in April 2022.
  • Operating expenses for the twelve-month period in 2023 declined by 52% to $10.9 million, compared with $22.8 million for 2022.
  • Adjusted EBITDA loss (Non-GAAP, as defined below) for Fiscal Year 2023 improved to $8.7 million, compared with $11.4 million, for 2022.
  • The Company will host a webcast today at 5:30 p.m. EDT to discuss the financial results and provide a corporate update.

CAPREIT Announces Renewal of Normal Course Issuer Bid

Retrieved on: 
Wednesday, March 20, 2024
CAPREIT, Trustee, Toronto Stock Exchange, Trust, TSX, Calendar, Acquisition

TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) today announced that the Toronto Stock Exchange (the “TSX”) has accepted CAPREIT’s notice of intention to renew its normal course issuer bid (“NCIB”) for its trust units (“Units”).

Key Points: 
  • TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) today announced that the Toronto Stock Exchange (the “TSX”) has accepted CAPREIT’s notice of intention to renew its normal course issuer bid (“NCIB”) for its trust units (“Units”).
  • Although CAPREIT intends to purchase Units under its NCIB, there can be no assurance that any such purchases will be made.
  • CAPREIT will enter into an automatic purchase plan during the term of the NCIB.
  • The automatic purchase plan will allow for purchases by CAPREIT’s broker of Units during certain pre-determined blackout periods.